Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.64Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: 0.69%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical development programs and strong financial positioning, offset by increased net loss and expenses. The promising clinical data and potential for blockbuster revenue suggest a positive outlook.Company Guidance
During the Celcuity Fourth Quarter and Full Year 2024 Financial Results Webcast Conference Call, several key metrics were discussed. The company reported a net loss of $36.7 million, or $0.85 per share, for the fourth quarter, compared to $18.8 million, or $0.65 per share, in the same period the previous year. For the full year 2024, the net loss totaled $111.8 million, or $2.83 per share, up from $63.8 million, or $2.69 per share, in 2023. The non-GAAP adjusted net loss for Q4 2024 was $32.3 million, or $0.75 per share, compared to $17.6 million, or $0.61 per share, in Q4 2023. For the full year, the non-GAAP adjusted net loss was $101.9 million, or $2.58 per share, versus $57.8 million, or $2.44 per share, in 2023. Research and development expenses rose to $33.5 million for the fourth quarter and $104.2 million for the year, driven by ongoing clinical trials. Celcuity ended the year with $235.1 million in cash and equivalents, up from $180.6 million at the end of 2023, following financing activities that raised $138.4 million.Progress in Clinical Development Programs
Celcuity completed enrollment of the PIK3CA wild-type cohort in the VIKTORIA-1 Phase III study and selection of approximately 200 sites for the VIKTORIA-2 Phase III study. The Phase Ib dose escalation study for prostate cancer is ongoing and on track for preliminary data by mid-2025.
Potential Blockbuster Revenue
Celcuity estimates that nearly 200,000 late-stage cancer patients globally could be eligible for treatment with gedatolisib, potentially generating blockbuster revenue if regulatory approvals are obtained.
Encouraging Overall Survival Data
Preliminary overall survival data from the Phase Ib study showed promising results, with median overall survival of 77 months for first-line patients and 34 months for second-line patients, compared favorably to published data.
Strong Financial Position
Celcuity ended fiscal 2024 with $235.1 million in cash, cash equivalents, and short-term investments, an increase of $54.5 million from the previous year.
---
CELC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CELC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $10.11 | $9.29 | -8.11% |
| Nov 14, 2024 | $14.11 | $12.66 | -10.28% |
| Aug 14, 2024 | $16.33 | $15.77 | -3.43% |
| May 15, 2024 | $17.23 | $17.66 | +2.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Celcuity (CELC) report earnings?
Celcuity (CELC) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is Celcuity (CELC) earnings time?
Celcuity (CELC) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CELC EPS forecast?
Currently, no data Available
---